Ceribell Aktie News

SUNNYVALE, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 45th Annual Growth Stock Conference. The presentation will take pla...

CeriBell, Inc. (NASDAQ:CBLL ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Xingjuan Chao - Co-Founder and Chief Executive Officer Scott Blumberg - Chief Financial Officer Conference Call Participants Stephanie Piazzola - Bank of America Margaret Andrew - William Blair Josh Jennings - TD Cowen John Young - Canaccord Jeffrey Cohen - Ladenburg Thalmann Operator Hell...

SUNNYVALE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended March 31, 2025.

SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Bank of America Securities 2025 Health Care Conference. The presentation will t...

Ceribell is one of only 51 companies in the U.S. to achieve FedRAMP High authorization Ceribell's breakthrough technology can now be deployed in federal healthcare facilities, including U.S. Department of Veterans Affairs hospitals, helping clinicians deliver faster diagnosis and treatment for patients at risk of non-convulsive seizures SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Ceri...

SUNNYVALE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Thursday, May 8, 2025.

SUNNYVALE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next generation Ceribell Clarity™ algorithm for the detection of ...

CeriBell, Inc. (NASDAQ:CBLL ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Brian Johnston - Gilmartin Group Xingjuan Chao - President and Chief Executive Officer Scott Blumberg - Chief Financial Officer Conference Call Participants Stephanie Piazzola - Bank of America Robert Marcus - JPMorgan Chase & Co. Macauley Kilbane - William Blair & Company Joshua Jen...